Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.

Pharma Cost Trends: Takeda vs. Agios

__timestampAgios Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014100371000520990000000
Thursday, January 1, 2015141827000535405000000
Friday, January 1, 2016220163000558755000000
Sunday, January 1, 2017292681000495921000000
Monday, January 1, 20181397000659690000000
Tuesday, January 1, 201913170001089764000000
Wednesday, January 1, 20202805000994308000000
Friday, January 1, 2021187770001106846000000
Saturday, January 1, 202217040001244072000000
Sunday, January 1, 202395040001431505000000
Monday, January 1, 202441650001431505000000
Loading chart...

Unleashing the power of data

Cost of Revenue Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. Takeda Pharmaceutical Company Limited, a global leader, and Agios Pharmaceuticals, Inc., a pioneering biotech firm, present a fascinating contrast in cost of revenue trends from 2014 to 2023. Takeda's cost of revenue has shown a robust upward trajectory, peaking at approximately 1.43 trillion in 2023, reflecting its expansive global operations and diverse product portfolio. In contrast, Agios Pharmaceuticals, with a focus on innovative therapies, experienced a more volatile pattern, with costs fluctuating significantly, peaking in 2017 and then stabilizing at lower levels. This divergence highlights the strategic differences between a large-scale pharmaceutical giant and a nimble biotech innovator. Notably, the data for 2024 is incomplete, indicating potential shifts in the coming year. These insights underscore the importance of strategic cost management in maintaining competitive advantage in the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025